What Are the Fundamentals Of Zimmer Biomet (ZBH)?

Zimmer Biomet logged a -0.1% change during today's afternoon session, and is now trading at a price of $124.89 per share. The S&P 500 index moved 0.2% and the Nasdaq posted a -0.0% change. ZBH's trading volume is 247,027 compared to the stock's average volume of 1,246,544.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The large-cap Healthcare company has 19,500 full time employees and is based in Warsaw, IN. Zimmer Biomet has returned a 0.8% dividend yield over the last 12 months.

Zimmer biomet Is Likely Overvalued:

Compared to the Healthcare sector's average of 13.21, Zimmer Biomet has a trailing twelve month price to earnings (P/E) ratio of -186.1 and, based on its Eps guidance of 8.73, an expected P/E ratio of 14.3. The firm's price to earnings growth (PEG) is 2.35, which indicates that it is overvalued in terms of its expected rate of earnings growth. Furthermore, Zimmer Biomet's price to book (P/B) ratio is 2.1 compared to its sector average of 4.07.

There is Mixed market sentiment About Zimmer Biomet:

22 analysts are following Zimmer Biomet and have set target prices ranging from $95 to $145 per share. On average, they have given the company a rating of hold. At today's prices, ZBH is trading 0.68% away from its average analyst target price of $124.05 per share, implying an analyst consensus of little upside potential for the stock. The company has a very low short interest since 1.5% of the company's shares are tied to short positions. Institutions own 92.0% of Zimmer Biomet's shares, while the insider ownership rate stands at 0.07%. The biggest shareholder is Vanguard Group, Inc. (The) with a 11.24% stake in the company worth approximately $2,476,611,423.00.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.